Matthew Weston
Stock Analyst at UBS
(4.26)
# 1,272
Out of 4,411 analysts
338
Total ratings
71.6%
Success rate
9.9%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Hold | 1,940p | $1,950.00 | -0.51% | 17 | Jun 15, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €52.00 | $36.01 | +44.40% | 19 | Jun 9, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 116.00 | $119.70 | -3.09% | 45 | Jun 8, 2026 | |
| ETR: MRK Merck KGaA | Maintained: Buy | €150.00 | $132.05 | +13.59% | 34 | May 13, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | CHF 384.00 → CHF 376.00 | $324.00 | +16.05% | 55 | May 13, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 332.00 | $280.30 | +18.44% | 26 | May 8, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,600p | $13,284.00 | +32.49% | 65 | Apr 30, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €88.00 | $75.66 | +16.31% | 14 | Apr 24, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Hold | €240.00 | $230.70 | +4.03% | 28 | Apr 23, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Maintained: Hold | €220.00 | $176.30 | +24.79% | 15 | Apr 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 200.00 | $171.25 | +16.79% | 10 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $115.17 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 750.00 | $494.40 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | $155.50 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $310 | $43.55 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $150.93 | n/a | 1 | Jul 5, 2017 |
GSK plc
Jun 15, 2026
Maintained: Hold
Price Target: 1,940p
Current: $1,950.00
Upside: -0.51%
Bayer Aktiengesellschaft
Jun 9, 2026
Maintained: Buy
Price Target: €52.00
Current: $36.01
Upside: +44.40%
Novartis AG
Jun 8, 2026
Maintained: Hold
Price Target: CHF 116.00
Current: $119.70
Upside: -3.09%
Merck KGaA
May 13, 2026
Maintained: Buy
Price Target: €150.00
Current: $132.05
Upside: +13.59%
Roche Holding AG
May 13, 2026
Maintained: Buy
Price Target: CHF 384.00 → CHF 376.00
Current: $324.00
Upside: +16.05%
Novo Nordisk A/S
May 8, 2026
Maintained: Hold
Price Target: kr 332.00
Current: $280.30
Upside: +18.44%
AstraZeneca PLC
Apr 30, 2026
Maintained: Buy
Price Target: 17,600p
Current: $13,284.00
Upside: +32.49%
Sanofi
Apr 24, 2026
Maintained: Hold
Price Target: €88.00
Current: $75.66
Upside: +16.31%
Sartorius Aktiengesellschaft
Apr 23, 2026
Maintained: Hold
Price Target: €240.00
Current: $230.70
Upside: +4.03%
Sartorius Stedim Biotech S.A.
Apr 17, 2026
Maintained: Hold
Price Target: €220.00
Current: $176.30
Upside: +24.79%
Apr 13, 2026
Maintained: Buy
Price Target: CHF 200.00
Current: $171.25
Upside: +16.79%
Nov 1, 2024
Maintained: Buy
Price Target: $125
Current: $115.17
Upside: n/a
Jan 27, 2022
Maintained: Buy
Price Target: CHF 750.00
Current: $494.40
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: $155.50
Upside: n/a
Nov 2, 2018
Maintained: Hold
Price Target: $310
Current: $43.55
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $150.93
Upside: n/a